Revolutionizing Cancer Diagnostics: The Rise of Liquid Biopsy

The landscape of cancer diagnostics is undergoing a seismic shift, driven by the advent of liquid biopsy technology.This minimally invasive approach, which analyzes circulating tumor DNA (ctDNA) in blood samples, offers a promising choice to conventional tissue biopsies. Liquid biopsies hold the potential for earlier cancer detection, personalized treatment strategies, and improved patient outcomes. The global market for liquid biopsies is significant, estimated at approximately 130 trillion won (JP Morgan, 2021), reflecting the growing recognition of its clinical value.

Early diagnosis of multi-cancer using liquid biopsy technology is included in the ‘Top 10 Bio Future Promising Technology’ selected by the Ministry of Science and ICT, and its value and necessity are highlighted in Korea.

GC genome’s AI-Enhanced Liquid Biopsy: A New frontier in early Detection

GC Genome, a South Korean clinical analysis company specializing in disease diagnosis and personalized treatment, has emerged as a leader in the field of liquid biopsy. Founded in 2013, the company has experienced rapid growth, averaging over 20% annually in the last five years.Their core business encompasses health checkups, acid, cancer, and genetic diagnostic tests, serving over 1,000 hospitals across Korea and expanding its reach to 19 countries across the United States, Europe, the Middle East, and the Asia Pacific.

In September 2023, GC Genome launched ‘Ican Cancer’, a groundbreaking product leveraging an AI algorithm-based analysis method developed from their proprietary liquid biopsy technology. This innovative test can predict the presence of more than six major cancers from a single blood sample. The initial focus includes lung, liver, colon, pancreatic, esophageal, and ovarian cancers, with plans to expand the panel in the future.

Exceptional Accuracy Validated: 82% Detection Rate

The AI-based analysis method developed by GC Genome has demonstrated remarkable accuracy, achieving an 82.2% sensitivity rate based on data from over 7,000 clinical samples collected through leading university hospitals. This impressive performance has been validated through publication in the prestigious international journal Nature Communications, and also presentations at major international cancer conferences and recognition with the Best Thesis Award from the 19th Korea Jin Dan Yusan Society.

The clinical results of this major technology have been published in the International Journal of Nature Communications, and are recognized at home and abroad through the announcement of major international cancer conferences and the 19th Korea Jin Dan Yusan Society’s Best Thesis Award.

Global Expansion and the Fight Against Cancer

GC Genome’s success extends beyond South korea, with the company securing a monopoly licensed-out agreement for its liquid biopsy analysis method in the Americas with US-based Genie Health. this technology transfer marks a significant milestone, making GC Genome the first Korean company to achieve such a feat in the liquid biopsy field. The company has also successfully expanded its test service to seven countries, solidifying its position as a global leader in liquid biopsy cancer diagnostics.

This expansion aligns with global initiatives like the United States’ Cancer Moonshot Project, which aims to reduce cancer mortality by 50% over the next 25 years. Early cancer detection through innovative technologies like GC Genome’s liquid biopsy plays a crucial role in achieving this enterprising goal.

The United States is pursuing the Cancer Moonshot Project with the goal of reducing cancer mortality rate by 50% over the next 25 years.It aims to actively respond to cancer screening and early discovery services, such as expanding access to cancer screenings, prevention of cancer before cancer, and providing the latest cancer innovation technologies to patients and communities. To this end, the company has begun a large -scale national clinical trial that adopts liquid biopsy technology to find cancer early.

The Future of Cancer Screening: Accessible, Accurate, and Personalized

GC Genome’s advancements in AI-powered liquid biopsy represent a significant step towards a future where cancer screening is more accessible, accurate, and personalized. By enabling early detection through a simple blood test, this technology has the potential to save lives and transform the way we approach cancer care. As the company continues to expand its global reach and refine its technology, the impact on patient outcomes is poised to be substantial.